Viewing data from:

METHAZOLAMIDE

ANDA

METHAZOLAMIDE | A040001 | ANI PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Methazolamide (2023)

Total Spending

$12.6M

Total Claims

41,087

Beneficiaries

10,447

Avg Cost/Unit

$3.20

Spending Trend

$17.9M(2019)→$17.8M(2020)→$15.9M(2021)→$14.5M(2022)→$12.6M(2023)

YoY Change:-14.5%

5yr CAGR:-8.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs3 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

FINE CHEMICALS CORP PTY LTDMETHAZOLAMIDE

DMF 79821989

DELMAR CHEMICALS INCMETHAZOLAMIDE

DMF 86761990

BIOPHORE INDIA PHARMACEUTICALS PVT LTDMETHAZOLAMIDE

DMF 323342017

MICRO LABS LTDMETHAZOLAMIDE USP

DMF 325142018

CHEMISCHE FABRIK WEYL GMBHInactiveMETHAZOLAMIDE

DMF 78561989

TCI AMERICAInactiveMETHAZOLAMIDE

DMF 78991989

CHONGQING NO. 5 PHARM. FACTORYInactiveMETHAZOLAMIDE

DMF 99351992

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 25MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 30, 1993

No patent or exclusivity listings for this strength.

#002 — 50MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 30, 1993